Scarica l'app Stockscreener
6.76
2.45%
-0.17
Dopo l'orario di chiusura:
6.77
0.010
+0.15%
Precedente Chiudi:
$6.93
Aprire:
$6.82
Volume 24 ore:
3.01M
Relative Volume:
0.46
Capitalizzazione di mercato:
$2.37B
Reddito:
$143.05M
Utile/perdita netta:
$-145.99M
Rapporto P/E:
-15.79
EPS:
-0.4282
Flusso di cassa netto:
$-134.06M
1 W Prestazione:
+4.32%
1M Prestazione:
+5.30%
6M Prestazione:
+19.86%
1 anno Prestazione:
+133.10%
Intervallo 1D:
$6.66
$6.97
Intervallo di 1 settimana:
$6.44
$7.58
Portata 52W:
$2.835
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Nome
Nuvation Bio Inc
Settore
Industria
Telefono
332-208-6102
Indirizzo
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
6.76 | 2.40B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-19 | Iniziato | B. Riley Securities | Buy |
| 2025-09-30 | Iniziato | Jefferies | Buy |
| 2025-04-23 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-26 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2021-03-08 | Iniziato | BTIG Research | Buy |
| 2021-03-08 | Iniziato | Cowen | Outperform |
| 2021-03-08 | Iniziato | Jefferies | Buy |
| 2021-03-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Nuvation Bio Inc Borsa (NUVB) Ultime notizie
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Nuvation Bio receives FDA fast track status for brain cancer drug - Investing.com South Africa
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - PR Newswire
Market Sentiment Around Loss-Making Nuvation Bio Inc. (NYSE:NUVB) - Moomoo
One NYSEListed Biotechnology Stock at Resistance Level – NUVB - kalkine.ca
Nuvation (NUVB) Results Breakdown: EPS Comes in Above Forecast for the Current Session; Share Response - Vinanet
Nuvation Bio (NUVB) Institutional Ownership 2026 - MarketBeat
This cancer drug stock could double as its treatment hits the market, JPMorgan says - CNBC
Nuvation wins new Overweight at J.P. Morgan (NUVB:NYSE) - Seeking Alpha
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know - Yahoo Finance
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
JPMorgan Initiates Nuvation Bio at Overweight With $13 Price Target - marketscreener.com
JPMorgan initiates Nuvation Bio stock coverage with overweight rating By Investing.com - Investing.com South Africa
JPMorgan initiates Nuvation Bio stock coverage with overweight rating - Investing.com
The Manufacturers Life Insurance Company Reduces Stake in Nuvation Bio Inc. $NUVB - marketbeat.com
Nuvation Bio (NUVB) Is Down 5.8% After Wider Q2 Loss Despite Surging Revenue And IBTROZI Focus - simplywall.st
Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Nuvation Bio (NUVB) Could Be 69% Undervalued On Earnings And IBTROZI Data Focus - Sahm
Brokers Set Expectations for Nuvation Bio FY2026 Earnings - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
559,180 Shares in Nuvation Bio Inc. $NUVB Bought by Renaissance Technologies LLC - marketbeat.com
Power Solutions International And 2 More Growth Stocks With Strong Insider Ownership - simplywall.st
HC Wainwright Predicts Nuvation Bio Q1 Earnings - MarketBeat
Nuvation Bio Q2 Earnings Call Highlights - marketbeat.com
Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Nuvation Bio(NUVB.US), With a Forecast Between $12 to $21 - moomoo.com
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $13 - Moomoo
RBC Adjusts PT on Nuvation Bio to $20 From $19, Maintains Outperform Speculative Risk Rating - marketscreener.com
Why Nuvation Bio (NUVB) Is Down 8.8% After Surging Q2 2026 Revenue and IBTROZI Data Tease - simplywall.st
NUVB SWOT Analysis: Revenue Surge Amidst Ongoing Losses Revealed in 10-Q Filing - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc - The National Law Review
Earnings call transcript: Nuvation Bio tops revenue forecasts in Q2 2026 - Investing.com Nigeria
Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results - MarketBeat
Nuvation Bio Inc. Stock 12‑Month Price Target Raised to $12.89, Implies 102% Upside - TradingView
Nuvation Bio earnings missed by $0.03, revenue topped estimates - Investing.com
Nuvation Bio Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Nuvation Bio reports Q2 revenue of $31.7 million - Investing.com
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Nuvation Bio Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (NUVB) Nuvation Bio Posts Q2 Net Loss of $0.18 per Share, vs. FactSet Est of $0.15 Loss - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q2 Revenue $31.7M, vs. FactSet Est of $27.0M - marketscreener.com
Nuvation Bio posts $31.7M Q2 revenue, $23.2M IBTROZI product sales and $62.8M net loss - TradingView
BRIEF-Nuvation Bio Q2 EPS USD -0.18 - TradingView
Nuvation Bio Inc Azioni (NUVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):